TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Incorporated in the People's Republic of China)
(Company Registration No.: 91120000103100784F)

RESOLUTIONS PASSED AT THE 6TH BOARD MEETING FOR FY2026

The board of directors (the "Board") and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the "Company") hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

On 7 August 2026, the Company duly convened its 6th Board meeting for the financial year ending 31 December 2026 ("**FY2026**") via a combination of a physical meeting and teleconference. The meeting was held in compliance with the applicable Company Law and Securities Law, as well as the Articles of Association of the Company. The following resolutions were duly passed at the meeting:

1. That the proposed entry by the Company, through its Health Technology Industry Development Branch (健康科技产业发展分公司), into an annual distribution agreement (年度经销协议) with Tianjin Pharmaceutical Group Taiping Medicine Co., Ltd. (津药太平医药有限公司) and Tianjin Zhongxin Medicine Co., Ltd. (天津中新医药有限公司) as an interested person transaction be approved.

   Mr. Guo Min, Ms. Wang Lei, Mr. Xing Jianhua and Ms. Mao Weiwen, each being an interested director, abstained from voting on this resolution.

   Please refer to the Company's separate announcement entitled *"The Proposed Entry into an Annual Distribution Agreement as an Interested Person Transaction*" released on the same date for further details.

2. That the proposed entry by the Company, through its Health Technology Industry Development Branch (健康科技产业发展分公司), into a warehousing and logistics cooperation agreement (委托储存三方物流合作协议) with Tianjin Pharmaceutical Group Taiping Medicine Co., Ltd. (津药太平医药有限公司) as an interested person transaction be approved.

   Mr. Guo Min, Ms. Wang Lei, Mr. Xing Jianhua and Ms. Mao Weiwen, each being an interested director, abstained from voting on this resolution.

   Please refer to the Company's separate announcement entitled *"The Proposed Entry into a Warehousing and Logistics Cooperation Agreement as an Interested Person Transaction*" released on the same date for further details.

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
7 August 2026